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Flt3 ligand expands CD103+ dendritic cells and
FoxP3+ T regulatory cells, and attenuates Crohn’s-like
murine ileitis
Colm B Collins,1 Carol M Aherne,2 Eo´in N McNamee,1 Matthew D P Lebsack,1
Holger Eltzschig,2 Paul Jedlicka,3 Jesu´s Rivera-Nieves4
ABSTRACT
Background Imprinting an effector or regulatory
phenotype on naı¨ve T cells requires education at
induction sites by dendritic cells (DC).
Objectives To analyse the effect of inflammation on the
frequency of mononuclear phagocytes (MP) and the
effect of altering their frequency by administration of
Flt3-L in chronic ileitis.
Methods Using a tumour necrosis factor (TNF) driven
model of ileitis (ie, TNFDARE) that recapitulates many
features of Crohn’s disease (CD), dynamic changes in the
frequency and functional state of MP within the inflamed
ileum were assessed by flow cytometry,
immunofluorescence and real-time reverse-transcription
PCR and by generating CX3CR1 GFP-reporter TNFDARE
mice. The effect of Flt3-L supplementation on the severity
of ileitis, and the frequency of CD103+ DC and of FoxP3+
regulatory T cells was also studied in TNFDARE mice.
Results CD11cHi/MHCII+ MP accumulated in inflamed
ilea, predominantly mediated by expansion of the
CX3CR1
+ MP subpopulation. This coincided with
a decreased pro-regulatory CD103+ DC. The phenotype
of these MP was that of activated cells, as they
expressed increased CD80 and CD86 on their surface.
Flt3-ligand administration resulted in a preferential
expansion of CD103+ DC that attenuated the severity of
ileitis in 20-week-old TNFDARE mice, mediated by
increased CD4+/CD25+/FoxP3+ regulatory T cells.
Conclusions Results support a role for Flt3-L as
a potential therapeutic agent in Crohn’s-like ileitis.
INTRODUCTION
The gastrointestinal tract is constantly exposed to
a vast array of food, bacterial, protozoan and viral
antigens. In this microenvironment the immune
system must maintain tolerance to self-antigens,
food and commensal microflora, while remaining
poised to mount robust responses to enteral path-
ogens. Through constant antigen sampling,
antigen-presenting cells play a critical role in
intestinal immune surveillance and in limiting over-
reactive inflammatory responses. Failure of the pro-
regulatory arm of the immune response has been
implicated in the development of chronic inflam-
matory conditions such as Crohn’s disease (CD).
CD is a chronic inflammatory bowel disease (IBD),
typified by transmural intestinal inflammation
involving the ileum in 60% of patients. Anti-
tumour necrosis factor (TNF) strategies are initially
effective in up to 70% of patients,1 yet sustained
remission drops significantly at 1 year,2 leaving an
unmet need for newer therapeutics in IBD. Strate-
gies that target other pathways of the chronic
inflammatory cascade must therefore be identified.3
Mononuclear phagocytes (MP) in the intestine
can be broadly divided into several functionally
distinct subsets, some of which express chemokine
receptors4 (eg, CX3CR1) or specific cell adhesion
molecules (ie, CD103, integrin aE). This CD103+
subset may or may not express CD11b and they are
classified as dendritic cells (DC).5 CX3CR1 is
a chemokine receptor, which binds its cognate
ligand CX3CL1 or fractalkine,6 a chemokine ligand
that exists as a membrane-bound potent arrest
chemokine or acts as a soluble chemoattractant on
proteolytic cleavage.7 CX3CR1+ cells have been
shown to drive pro-inflammatory Th17 responses
and play a vital role in bacterial clearance in the
intestine.8 They have a significantly higher capacity
to sample antigens compared with CD103+ DC4 9
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Significance of this study
What is already known on this subject?
< CD103+ dendritic cells preferentially induce
regulatory gut homing T cells.
< Regulatory T cells (Tregs) prevent and treat
established disease in mouse models of inflam-
matory bowel disease.
< Flt3-ligand preferentially expands CD103+ DC in
mice and humans.
What are the new findings?
< There is expansion of mononuclear phagocytes
in chronic ileitis. There is an altered ratio of
CX3CR1+ mononuclear phagocytes and
CD103+ DC during chronic ileitis.
< Flt3-ligand administration preferential expands
CD103+ DC, FoxP3+ Tregs in vivo and
attenuates chronic murine ileitis.
How might it impact on clinical practice in the
foreseeable future?
< Flt3-ligand has been shown to be safe and
effective in human clinical trials previously;
these findings therefore have potential trans-
lational value for the treatment of patients with
inflammatory bowel disease.
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due to their ability to extend dendrites into the lumen. CX3CR1+
cells exhibit significantly lower turnover rates, reduced homing to
the mesenteric lymph nodes (MLN) and impaired induction of T
cell proliferation compared with CD103+ DC.4
Central to the maintenance of a controlled inflammatory
response is the induction of regulatory Tcells (Tregs). A subset of
Tregs is defined by their expression of the transcription factor
forkhead box P3 (FoxP3) and release of IL-10.10 11 Treg expansion
has been reported in human IBD and in murine models.12e15
Induction of small intestinal homing (CCR9+/a4b7+) on Tcells
is mediated by the release of retinoic acid (RA), predominantly
from CD103+ DC, which in the presence of transforming growth
factor b (TGFb)16 17 promote induction of a regulatory pheno-
type in naïve T cells.18 Compared with CD103+ DC, CX3CR1+
cells express significantly lower levels of aldh1a2 mRNA, which
encodes retinaldehyde dehydrogenase 2 (RALDH2), an enzyme
critical for the conversion of retinal to RA.16
Generation of CD103+ DC is partly mediated by the poly-
onymous FMS-like tyrosine kinase 3 (Flt3) through interaction
with its cognate ligand (Flt3-L), a type-1 transmembrane or
soluble protein similar in size and structure to other haemato-
poietic growth factors like CSF-1 and KIT ligand.19 Originally
identified in mice,20 Flt3 was soon found in humans.21 Flt3
mRNA was detected in pre-B cell, myeloid and monocytic line-
ages, whereas Flt3-L mRNA was detected in most cell lines in
humans and mice.22
Both Flt3 and Flt3-L are highly conserved between mice and
humans. Human Flt3 ligand can bind and activate mouse Flt3
receptor,23 resulting in bone marrow hyperplasia and stimula-
tion of haematopoetic stem and progenitor cell proliferation.
While Flt3-L has been shown to synergise with multiple
cytokines and growth factors, cytokines such as TNF and
TGFb abrogate its ability to stimulate growth of murine
haematopoietic progenitors.24 The use of Flt3-L to prefe-
rentially expand MP in mice has become commonplace for
the study of MP function since it was first discovered25;
however, its preferential proliferative effect on CD103+ DC
was identified recently.5
The role that MP play during induction and perpetuation of
CD is not known. To begin to understand their potential
contribution to CD, we analysed the relative abundance of MP
subsets in a relevant chronic model of Crohn’s-like ileitis
generated by deletion of 69 bp within the AU-rich element
(ARE) of the TNF gene in mice (ie, TNFDARE). The ARE
deletion stabilises TNF mRNA, resulting in systemic TNF
overproduction and development of chronic inflammation
localised to the terminal ileum, reminiscent of human CD
in its histological features and the pivotal role played by TNF
in its pathogenesis.26e28 Here we examined the potential role
of intestinal MP subsets in the regulation of chronic ileitis in the
TNFDARE model: one of only two mouse models that recapit-
ulate the histopathological features of CD. First we investigated
whether the inflammatory process affected the overall frequency
of CD11c+/MHC+ MP and their activation state. We next
assessed whether particular MP subsets (CX3CR1+, CD103+)
were expanded under conditions of chronic inflammation. We
then investigated the capacity of Flt3-L to expand particular MP
subsets under conditions of chronic inflammation, and its Treg
progeny to modulate disease severity.
MATERIALS AND METHODS
Mice
The B6.129S-Tnftm2Gkl/Jarn strain, as previously described,29 was
kept under specific-pathogen-free conditions. Experimental
animals were heterozygous for the DARE mutation or homozy-
gous wild-type (WT), which served as controls. CX3CR1GFP/GFP
mice and CD103/ mice on the C57BL6/J background were
obtained from Jackson Laboratories (Bar Harbor, Maine, USA)
and crossed with TNFDARE or WT mice to generate WT/
CX3CR1GFP/+ and TNFDARE/CX3CR1GFP/+ mice. Faecal
samples were negative for Helicobacter, protozoa and helminthes.
All animals were handled according to procedures approved by
the institutional committee for animal use.
Lymphocyte isolation
Splenocytes, MLN and lamina propria (LP) mononuclear cells
were isolated as previously described.30 Briefly spleens and MLN
were passed through a 70 mm filter, red cells lysed and single cell
suspensions counted. Intraepithelial lymphocytes and epithelial
cells were removed from whole ileal tissue using 1 mM EDTA
and vigorous shaking; tissues were then digested in collagenase
VIII (Sigma Aldrich, St Louis, Missouri, USA), filtered and
counted prior to staining.
Flow cytometry
Cells from indicated compartments were incubated with fluo-
rescent rat anti-mouse antibodies, including those against:
mouse CD11c (N418), MHCII (M5/114.15.2), F4/80 (BM8),
CD103 (2E7), CD80 (16-10A1), CD86 (GL-1), CD3 (17A2), CD4
(RM4-5), CD25 (PC61.5), E-cadherin (36), and FoxP3 (FJK16S),
or their respective isotype controls prior to fixation with 2%
paraformaldehyde. Additional controls included cells isolated
from CD103-deficient mice. FoxP3 staining was performed
according to the manufacturer ’s instructions (eBiosciences, San
Diego, California, USA). Intracellular cytokine staining was
performed by stimulating unfractionated cells with 20 ng/ml
phorbol myristate acetate, 1 mg/ml ionomycin and 15 mM
monensin for 5 h (13106 cells/well) prior to fixation and
permeabilisation using the FoxP3 staining kit as above.
Cells were analysed using the FACS Canto system (Beckton-
Dickinson Immunocytometry Systems, San José, California,
USA). Post-analyses were performed using FLOWJo software
(Tree Star, Ashland, Oregon, USA). Unless otherwise stated
CD11cHi/MHCII+ cells were previously gated on F4/80Neg.
Primary cell culture experiments
Freshly isolated cells from the LP of 20-week-old WT and
TNFDARE mice were cultured in complete medium (RPMI
supplemented with 10% foetal bovine serum, 2 mM L-glutamine,
100 IU penicillin, 100 mg/ml streptomycin; Invitrogen, Carlsbad,
California, USA) in the presence or absence of 5 mg/ml LPS for
24 h.
RNA isolation, cDNA synthesis and real-time PCR
Ileal tissue was stored in RNAlater (Invitrogen) prior to mRNA
isolation (mRNA isolation kit, Qiagen, Valencia, California,
USA). Freshly isolatedMP fromTNFDAREmicewere enriched by
positive selection (CD11c+ N418, Miltenyi Biotec, Auburn, CA,
USA) and FACS sorted based on CD11cHi/MHCII+ and CD103
expression. Transcript quantification was performed using
PowerSybr Green and the AB7900 real-time PCR system (Applied
Biosystems, Foster City, California, USA). GAPDH served as an
endogenous control. RALDH2 and CX3CR1 were assayed with
QuantiTect primers (QT00120477, QT00203434, Qiagen).
Flt3 ligand treatment studies
Twenty-week-old TNFDARE mice received daily intraperitoneal
Flt3-L injections (10 mg/injection) or phosphate-buffered saline
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for 9 days. Tissues were collected 24 h after the last injection. In
some experiments mice were also administered anti-CD25
antibody 200 mg/injection on days 3, 0, 3 and 6 (eBioscience,
PC65.1). Recombinant human Flt3-L was provided by Dr Robert
Mittler at the Emory Vaccine Center (Atlanta, Georgia, USA).
Statistics
Statistical analyses were performed using the Student t test with
Graphpad Prism Data Analysis software (GraphPad Software, La
Jolla, California, USA). Data were expressed as mean6SEM.
Statistical significance was set at p<0.05.
RESULTS
Mononuclear phagocytes increased in TNFDARE mice
compared with WT controls
We evaluated the frequency of CD11c+/MHCII+ MP in spleen,
MLN and terminal ileal LP of TNFDARE mice at 4 and at 20
weeks of age compared with WT (figure 1A) using the gating
strategy outlined in figure 1B. The total number of MP in the
spleen was significantly increased in TNFDARE mice compared
with WTat 4 (p<0.01) and 20 weeks of age (p<0.05) (figure 1A).
This coincided with a significant increase in the MLN at 4
(p<0.05) and at 20 weeks of age (p<0.001). Similarly in the LP,
there was a significant increase in MP in TNFDARE mice at 4
(p<0.05) and at 20 weeks of age (p<0.01). Evaluation of
CD11c+/MHCII+ cells by flow cytometry demonstrated the
presence of two distinct subsets based on relative expression of
CD11c, one CD11cHi and the other CD11cIntermediate. Assess-
ment of these two subsets, which were both expanded,
demonstrated that the CD11cHi subset contained CD103+ DC,
whereas the CD11cIntermediate cells were positive for CD11b
(figure 1C). Based on the finding that the majority of CD103+
DC were found within the CD11cHi compartment, we focused
on this population in subsequent studies. Representative scatter
and zebra plots illustrate the effect of inflammation on MP
subsets at 20 weeks of age. This increase in MP coincided with
increased disease severity in TNFDARE mice (supplemental
figure 1). Thus, MP accumulate within the inflamed terminal
ileal LP of TNFDARE mice and the CD103+ subset express high
levels of CD11c.
CD103+/CD11b+ and CD103+/CD11bNeg DC subsets decreased
in the chronically inflamed ilea of TNFDARE mice
Recently, Varol et al demonstrated two distinct pro-regulatory
DC subsets present in the small intestinal LP and GALT, which
were CD103+/CD11bNeg or CD103+/CD11b+.5 Thus, we
extended our analyses to include examination of these subsets
(figure 1D). The frequency of CD103+/CD11bNeg DC was
significantly decreased in 20-week-old TNFDARE LP compared
with WTcontrols (p<0.01); similarly the frequency of CD103+/
CD11b+ DC were decreased in inflamed ilea compared with WT
controls (p<0.05). In contrast the CD103Neg/CD11b+ subset
was expanded in inflamed ilea compared with WT mice
(p<0.01). Expression of RALDH2 mRNA transcripts, the key
enzyme for the production of RA by pro-regulatory DC, was
examined in CD103+ and CD103Neg DC sorted from the MLN
and LP of 20-week-old TNFDARE mice. Real-time PCR revealed
significantly higher expression of RALDH2 in CD103+ DC
compared with CD103Neg MP from the MLN (p<0.01) and LP
(p<0.01) of 20-week-old TNFDARE mice, consistent with
previous findings in WT mice (supplemental figure 6).16 Thus,
there is a deficiency of RA-producing tolerogenic CD103+ DC
during chronic ileitis.
Mononuclear phagocytes from the LP of TNFDARE mice
displayed an activated phenotype
To determine whether chronic inflammation influenced the
activation state of MP within the LP, we examined the expres-
sion of the co-stimulatory molecules CD80 and CD86 in freshly
isolated unfractionated (total) MP, or those gated based on the
expression of CD103. MP isolated from 20-week-old TNFDARE
LP expressed higher mean fluorescence intensities (MFI) for both
CD80 and CD86 compared with age-matched WT controls
(figure 2A). Mean MFI for CD80 in unfractionated MP was
7196243 in WT compared with 23836381 in TNFDARE mice
(p<0.01), while in CD103+ DC it was 11856224 in WT
compared with 31696338 in TNFDARE mice (p<0.05). Simi-
larly, MFI on CD103Neg MP was 8466172 in WTcompared with
26956138 in TNFDARE mice (p<0.01).
When the expression of CD86 was assessed on total DC, the
MFI in WT mice was 26966450 compared with 636761320 in
TNFDARE mice (p<0.05). Those DC positive for CD103 had an
MFI of 30516107 in WTcompared with 8729689 in TNFDARE
mice (p<0.01); within the CD103Neg MP subset the MFI was
25466531 in WTcompared with 617061324 in TNFDARE mice
(p<0.05; figure 2A). Representative histograms of the above data
are presented in figure 2B.
LPS treatment negated the differences present between MP
from inflamed and non-inflamed mice as CD80 and CD86 MFI
increased in WT MP to levels comparable with TNFDARE MP
levels for both markers (data not shown). Therefore, a higher
fraction of MP isolated from the terminal ileal LP of TNFDARE
mice displayed an activated phenotype.
CX3CR1
+ mononuclear phagocytes increased while CD103+ DC
decreased in chronic ileitis
To evaluate the relative frequency of CX3CR1+ and CD103+ MP
in TNF-mediated ileitis, we generated a CX3CR1 reporter
TNFDARE substrain (TNFDARE/CX3CR1GFP/+). Blinded histo-
logical examination of the ilea of the resultant progeny revealed no
significant differences in the severity of ileitis between TNFDARE/
CX3CR1GFP/+ and TNFDARE/CX3CR1+/+ mice (supplemental
figure 2). Flow cytometric analysis of 20-week-old TNFDARE/
CX3CR1GFP/+ MP (CD11cHi/MHC+/F4/80Neg) showed no
significant differences in the CX3CR1+:CD103+ subset ratio in
the spleen; however, in the MLN there was an expansion of the
CX3CR1+ MP subset (p<0.01; figure 3A,B) and a decrease in
CD103+ DC (p<0.05). Similarly, in the ileal LP the proportion of
CX3CR1+ increased (p<0.05) while CD103+ DC decreased
(p<0.01) (figure 3A). Increased CX3CR1+ MP coincided with up-
regulation of CX3CR1 mRNA transcripts within the terminal ilea
of TNFDARE compared with WT mice (supplemental figure 3).
Representative scatter and zebra plots illustrate the inflammation-
driven changes on the indicated subsets present in ilea at 20 weeks
of age (figure 3B). Increased frequency of CX3CR1+ and decreased
CD103+ MP was similarly observed when cells expressing the
macrophage marker F4/80 were included in the analyses, as F4/80
is expressed predominantly by cells that lack CD103 (supple-
mental figure 4). When the frequency of CX3CR1+ cells was
analysed within MHC+/CD11b+ cells, the majority (around 90%)
expressed CX3CR1 (supplemental figure 5). Hence, CX3CR1+ MP
increase, whereas CD103+ DC decrease in the MLN and terminal
ilea of chronically inflamed TNFDARE mice.
Flt3-L preferentially expands CD103+ pro-regulatory MP subsets
in TNFDARE mice
To begin to understand whether Flt3-L might alter the
frequency of specific MP during chronic ileitis, we assessed its
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effect on the frequency of MP in 20-week-old vehicle- and Flt3-
L-treated TNFDARE mice. Flt3-L supplementation significantly
increased the absolute number of CD11cHi/MHCII+ DC in the
spleen (p<0.01), MLN (p<0.001) and LP (p<0.05) of TNFDARE
mice compared with vehicle-treated age-matched controls
(figure 4A). Representative zebra plots illustrate these findings
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Figure 1 Increased mononuclear phagocytes (MP) in TNFDARE mice. (A) Total cell counts from indicated organs of TNFDARE mice aged 4 and 20
weeks of age compared with wild-type (WT) littermate controls (mean6SEM from three individual experiments, n¼3 mice/experiment with cells
pooled per genotype and time-point. *p<0.05, **p<0.01, ***p<0.001). (B) Representative scatter plots illustrating the gating strategy utilised, which
included F4/80+ cells. (C) Representative zebra plots and histograms illustrating the expression of CD103 and CD11b within CD11cHi/MHCII+ and
CD11cIntermediate/MHCII+ MP in the lamina propria (LP) of 20-week-old WT and TNFDARE mice. (D) The percentage of indicated MP subsets was
assessed by flow cytometry from the LP of TNFDARE and WT mice at 20 weeks of age (mean6SEM, n¼4, *p<0.05, **p<0.01). (E) Representative
zebra and contour plots from LP MP of WT and TNFDARE mice. MLN, mesenteric lymph nodes.
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(figure 4B). Subset analysis of the expanded MP population in
the inflamed LP revealed preferential expansion of the absolute
numbers of unfractionated CD103+ DC (p<0.001), the
CD103+/CD11bNeg subset (p<0.001) and the CD103+/
CD11b+ subset (p<0.001; figure 4C). The effect of Flt3L on
CD103Neg MP subset was not statistically significant. Repre-
sentative histograms demonstrate a shift in the expression of
CD103 (figure 4D).
Real-time PCR analysis of ilea from vehicle and Flt3-
L-treated demonstrated an up-regulation of RALDH2, the
enzyme expressed predominantly by CD103+ MP, critical for
the generation of retinoic acid (p<0.05) and a decreased
expression of CX3CR1 mRNA transcript (p<0.05; supp-
lemental figure 7). Furthermore, the frequency of the
E-cadherin+ subset, which was increased in the LP of 20-
week-old TNFDARE mice relative to WT littermates (p<0.05),
significantly decreased after Flt3-L administration (p<0.001;
supplemental figure 8).
Regulatory T cells increased after Flt3-L treatment in TNFDARE
mice
Having demonstrated an expansion of CD103+ DC in the LP of
TNFDARE mice treated with Flt3-L, we examined whether
increased CD103+ DC resulted in the induction of regulatory
CD4+/CD25+/FoxP3+ Tregs. The absolute number of Tregs
significantly increased in 20-week-old Flt3-L-treated TNFDARE
mice spleen (p<0.01), MLN (p<0.01) and LP (p<0.05)
(figure 5A) compared with vehicle-treated controls; there was
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Figure 2 Mononuclear phagocytes (MP) from TNFDARE ileal lamina propria (LP) display an activated phenotype. (A) Expression of CD80 and CD86
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also an increase in the thymus of Flt3-L treated TNFDARE mice
(p<0.05). Representative zebra plots demonstrate that the
significant increase in total numbers of Tregs seen in the Flt3-
treated ileal LP coincides with an increased Treg frequency from
25% to 29% (p<0.05; figure 5B). Hence, stimulation of Flt3
drives induction of CD4+/CD25+/FoxP3+ Tregs.
Flt3 ligand administration attenuated chronic ileitis
Flt3-L preferentially expanded the CD103+ DC subset and its
Treg progeny.5 To determine whether Flt3-L administration may
affect the severity of ileitis during late disease, inflammation was
assessed in vehicle- and Flt3-L-treated mice by a pathologist in
a blinded fashion. Flt3-L supplementation significantly decreased
Figure 3 Increased CX3CR1
+:
CD103+ mononuclear phagocytes (MP)
ratio in the ileal lamina propria (LP) of
TNFDARE mice. (A) CX3CR1
+ and
CD103+ MP frequency in the spleen,
mesenteric lymph nodes (MLN) and LP
of 20-week-old WT/CX3CR1
GFP/+ and
TNFDARE/CX3CR1
GFP/+ mice
(mean6SEM from four independent
experiments, n¼3 mice/experiment;
*p<0.05, **p<0.01). (B)
Representative scatter and zebra plots
of the expression of CX3CR1
+ and
CD103+ MP gated on CD11cHi/MHCII+
cells from the LP of 20-week-old mice.
WT, wild-type.
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active (4.560.6% vs 1.560.3%; p<0.01), chronic (460.6% vs
260.7%; p<0.05), villus distortion (3.561% vs 160.5%; p<0.05)
and total inflammatory indices (1262% vs 561.4%; p<0.01)
compared with vehicle-treated controls (figure 6A). In addition,
histological hallmarks of ileitis such as villus distortion,
leucocyte infiltration, goblet cell hyperplasia and muscularis
hypertrophy were noticeably decreased (figure 6B). The anti-
inflammatory effect was dependent on regulatory T cells as
antibody-mediated depletion of functional Tregs with an anti-
CD25 antibody abrogated the protective effect of Flt3-L
(supplemental figure 9). Thus, Flt3-L administration exerts
a potent anti-inflammatory effect on chronic ileitis mediated by
Tregs.
DISCUSSION
MP, which include cells that express CX3CR1, CD103 (both
CD11b+ and CD11bNeg) and macrophages (CD11b+/F4/80+)
play a critical role in intestinal immune surveillance and regu-
lating inflammatory responses. Considerable progress has been
made recently in understanding the basic biology of MP in the
maintenance of normal gut homeostasis. MP subsets have been
identified that appear to be pro- or anti-inflammatory; however,
it is not known whether they play a role in the induction and/or
maintenance of chronic inflammatory conditions, such as IBD.
As such, this study aimed to investigate the effect of chronic
inflammation on the frequency of MP subsets in a murine model
of chronic ileitis and whether altering this frequency might be of
therapeutic value. We noticed expansion of MP in the inflamed
LP of TNFDARE mice. These MP have an activated surface
phenotype, consistent with exposure to bacterial antigens,
contain a higher proportion of CX3CR1+ cells and show
a reduced frequency of pro-regulatory CD103+ MP. We addi-
tionally show that Flt3-L attenuated established chronic ileitis in
20-week-old TNFDARE mice, via an expansion of CD103+ DC
and its regulatory CD4+/CD25+/FoxP3+ T cell progeny.
T cell receptor engagement and additional co-stimulatory
signals supplied by CD80 and CD86 are required to elicit T cell
responses. CD80 and CD86 are up-regulated on the surface of
activated MP and serve as surrogates for activation. MP infil-
trating the ileum of TNFDARE mice demonstrated increased
activation, in the absence of stimulation. Enhanced activation is
concordant with studies in other murine models of IBD32e34 and
in human IBD.35 MP activation can be reproduced by stimula-
tion with LPS36e38 and given the disruption of the epithelial
barrier associated with chronic ileitis,39 it is likely that increased
bacterial translocation contributes to the heightened activation
of MP in the LP of TNFDARE mice.
CX3CR1+ MP, also called antigen sampling cells,4 5 were found
to promote ATP-dependent Th17 differentiation. By contrast,
CD103+ DC produce RA and indoleamine 2,3-dioxygenase and
are critical for the induction of FoxP3+ Tregs in mice and
humans.16 17 40e43 Thus we hypothesised that an imbalance of
these populations may play a role in the pathogenesis of chronic
ileitis and examined their relative frequency in WT and
TNFDARE mice. Indeed we observed a subset imbalance with
increased CX3CR1+ and decreased pro-regulatory CD103+ MP in
TNFDARE mice compared with WT controls. The functional
implications of the expansion of the CX3CR1+ MP in the
TNFDARE model are unclear at this time and are the focus of
ongoing studies. Expansion of the CX3CR1+ subset has been
demonstrated in human chronic inflammatory conditions such as
atopic dermatitis.44 In separate studies, reconstitution of the
CX3CR1 subset exacerbated dextran sulphate sodium-mediated
colitis and impaired tissue repair in a TNF-dependent manner,5
whereas CX3CR1-deficient mice exhibited attenuated colitis.45
40 1.6 12 
1.2 
0.8 
0.4 
30 
20 
10 
9 
6 
3 
** ** 
* 
C
D
4
+
/
C
D
2
5
+
/
F
o
x
P
3
+
 
Vehicle Flt3-L 
Vehicle Flt3-L IgG  
CD25 APC Cy7 
Lamina propria MLN Spleen 
B 
A 
F
o
x
P
3
 
P
E
 
C
y
7
 25±1 
10
2
 10
5
 104 10
3
 
10
2
 
10
5
 
10
4
 
10
3
 
29±1 
10
2
 10
5
 10
4
 10
3
 
10
2
 
10
5
 
10
4
 
10
3
 
0.2 
10
2
 10
5
 10
4
 10
3
 
10
2
 
10
5
 
10
4
 
10
3
 
Vehicle Flt3-L Vehicle Flt3-L 
Figure 5 Increased CD4+/CD25+/FoxP3+ Tregs in Flt3-L-treated mice.
(A) Effect of Flt3-L administration on the absolute counts of CD4+/
CD25+/FoxP3+ Tregs in indicated organs isolated from vehicle- or Flt3-
L-treated 20-week-old TNFDARE mice (mean6SEM, n¼5 mice/group;
*p<0.05, **p<0.01). (B) Representative zebra plots display percent-
ages of FoxP3 and CD25 on CD4+ T cells from the lamina propria (LP) of
vehicle- and Flt3-L-treated mice using PE Cy7 IgG as a control for FoxP3
intracellular staining. MLN, mesenteric lymph nodes.
Vehicle Flt3-L 
6 
4 
2 
18 
6 
A
c
t
i
v
e
 
V
i
l
l
u
s
 
d
i
s
t
o
r
t
i
o
n
 
C
h
r
o
n
i
c
 
T
o
t
a
l
 
B
A
Vehicle Flt3-L Vehicle Flt3-L 
** 
12 
* 
** 
6 
4 
2 
6 
4 
2 
* 
Figure 6 Flt3-L administration attenuated chronic ileitis. (A) Inflam-
matory indices from ilea of 20-week-old TNFDARE mice treated with
vehicle or Flt3-L were assessed as described31 (mean6SEM, *p<0.05,
n¼5/treatment group). (B) Representative H&E micrographs of vehicle-
and Flt3-L-treated ilea of 20-week-old TNFDARE mice (103 magnifi-
cation, bars¼100 mm).
1160 Gut 2012;61:1154e1162. doi:10.1136/gutjnl-2011-300820
Inflammatory bowel disease
 o
n
 M
arch 10, 2020 at M
aynooth University Library. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2011-300820 on 7 November 2011. Downloaded from 
CD103+ DC preferentially drive the induction of a gut-
homing regulatory phenotype on naïve T cells in mice16 17 41e43
and humans42 in an RA/TGFb-dependent manner. We hypoth-
esised that CD103+ DC might be critical for the regulation of
chronic ileitis. While CD103 deficiency is in itself insufficient to
inhibit antigen presentation by MP,42 antibody depletion of
CD103+ DC exacerbated murine colitis, supporting a protective
function for this population.5 41
Previous studies have demonstrated that Flt3-L is required for
CD103+ DC proliferation46 47 and injection of Flt3-L has been
shown to increase the number of CD103+ DC and Tregs in the
mouse intestine.48 Thus, we next sought to determine whether
administration of Flt3-L might have a therapeutic effect in
ileitis. While Flt3-L has been shown previously to block induc-
tion of inflammation in a transfer-colitis model,48 this study is
the first to demonstrate attenuation of inflammation in
a chronic model. In our studies Flt3-L preferentially expanded
CD103+/CD11b+ and CD103+/CD11bNeg DC within the LP,
driving induction of CD4+/CD25+/FoxP3+ Tregs as has been
shown in mice16 17 41e43 and humans.42 Thus, Flt3-L adminis-
tration increased the frequency of CD103+ DC in the LP of
TNFDARE mice, expanded the Treg population and attenuated
TNF-mediated Crohn’s-like ileitis.
While this article has focused primarily on the pro-regulatory
capacity of CD103+ DC in chronic murine ileitis, it must be
noted that these are not the only DC population with a proven
capacity to expand in response to Flt3-L stimulation and also
induce Tregs. Previous studies have demonstrated the capacity of
Flt3-L to induce expansion of plasmacytoid DC,49 and migration
of this population from peripheral circulation to the inflamed
intestine has been proposed to correlate with disease severity in
ulcerative colitis and Crohn’s disease.50 Furthermore, an increase
in plasmacytoid DC in the intestinal lamina propria has been
demonstrated previously in a murine colitis model.51 Although
numerous studies have demonstrated that CD103+ DC do not
express B220,52 mature plasmacytoid DC may induce Tregs with
suppressive function. While the possible contribution of plas-
macytoid DC to the anti-inflammatory effect of Flt3-L warrants
further evaluation in this model, the capacity of CD103+ DC to
induce both gut-homing and regulatory phenotypes places these
cells firmly in the forefront of candidates for driving expansion
of Tregs seen in the inflamed intestine, leading to attenuation of
ileitis in vivo.
In summary, our studies examined the frequency of distinct
MP subsets in a mouse model that recapitulates many features
of CD and demonstrates the therapeutic effect Flt3-L supple-
mentation in a chronic model of IBD. As promoting T cell
regulation remains an attractive strategy for induction and
maintenance of remission in IBD, the preferential expansion of
pro-regulatory DC with Flt3-L may be further explored as
a novel biological therapy. The safety of Flt3-L administration
has been demonstrated in healthy human subjects53 and efforts
are currently underway to optimise the large-scale preparation
of bioactive progenipoietin-1, a fusion protein with dual-
agonistic properties for both G-CSFR and Flt3, which in vitro
has been shown to have synergistic effects on the expansion of
the CD103+ subset and its regulatory T cell progeny.54
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